Oncological Safety and Recurrence in the Surgical Treatment of Atypical Fibroxanthoma and Pleomorphic Dermal Sarcoma of the Scalp

被引:2
作者
Zeller, Johannes [1 ]
Kiefer, Jurij [1 ]
Braig, David [1 ,2 ]
Winninger, Oscar [1 ]
Kraus, Daniel [1 ]
Hagelstein, Salome [1 ]
Eisenhardt, Steffen U. [1 ]
机构
[1] Univ Freiburg, Med Ctr, Med Fac, Dept Plast & Hand Surg, D-79106 Freiburg, Germany
[2] Ludwig Maximilians Univ Munchen, Univ Hosp, Div Hand Plast & Aesthet Surg, D-80336 Munich, Germany
关键词
atypic fibroxanthoma; pleomorphic dermal sarcoma; dermal sarcoma; surgical treatment; RELATIVE WEIGHT; MANAGEMENT; MUTATIONS; FREQUENT; INDEXES; EUROPE;
D O I
10.3390/cancers14122869
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Atypical fibroxanthoma and pleomorphic dermal sarcoma represent two tumors on the spectrum of a rare dermal sarcoma entity. Close clinical presentation and nearly identical histologic features but distinct prognoses make proper treatment strategies challenging. We performed a retrospective analysis of 32 patients with AFX or PDS in the scalp to provide guidance regarding the extent of radical excision to achieve stable oncological outcomes and whether radical tumor resection on the scalps required complex soft-tissue reconstruction. Compared to AFX, PDS shows a more aggressive growth pattern with frequent satellite metastases and distant metastases. These require extensive resections for local control to achieve long-term remission in most PDS patients. Despite the limited elasticity of the scalp, plastic reconstructive procedures can obtain reliable soft tissue reconstruction, even for complete scalp defects. Due to their rarity, managing these tumors requires an interdisciplinary setting in a specialized sarcoma center. Atypical fibroxanthoma (AFX) and pleomorphic dermal sarcoma (PDS) are two distinct designations for a rare dermal sarcoma entity. These tumors arise predominantly in the sun-damaged skin of elderly patients. Although both AFX and PDS have a similar clinical presentation and nearly identical genetic features, they significantly differ in prognosis. Here we present a retrospective single-center chart review analyzing the outcomes of patients treated for dermal sarcoma. The radicality of the tumor-resection extent and soft-tissue reconstructive options were assessed. Patients between January 2010 and August 2021 were included. We recorded resection margins, tumor recurrence, overall survival, number of operations until complete tumor resection, and reconstructive procedures; any complications were recorded. Furthermore, we analyzed a subgroup of patients with satellite metastases. A total of 32 patients met the inclusion criteria (30 male, 2 female, median age of 77.5 years (interquartile range (IQR) 74-81)). Histopathology revealed AFX in 14 patients and PDS in 18 patients. Margin-free resection was achieved in 31 cases, and 27 patients were remission free over the reported period. The local recurrence rate was 5, and distant metastasis was detected in four cases. Of all the PDS cases, nine presented with satellite metastasis. No AFX had satellite metastases. Due to their rarity, managing these tumors requires an interdisciplinary setting in a specialized sarcoma center.
引用
收藏
页数:10
相关论文
共 34 条
  • [21] Genome-wide methylation profiling and copy number analysis in atypical fibroxanthomas and pleomorphic dermal sarcomas indicate a similar molecular phenotype
    Koelsche, Christian
    Stichel, Damian
    Griewank, Klaus G.
    Schrimpf, Daniel
    Reuss, David E.
    Bewerunge-Hudler, Melanie
    Vokuhl, Christian
    Dinjens, Winand N. M.
    Petersen, Iver
    Mittelbronn, Michel
    Cuevas-Bourdier, Adrian
    Buslei, Rolf
    Pfister, Stefan M.
    Flucke, Uta
    Mechtersheimer, Gunhild
    Mentzel, Thomas
    von Deimling, Andreas
    [J]. CLINICAL SARCOMA RESEARCH, 2019, 9
  • [22] Case of pleomorphic dermal sarcoma with systematic review of disease characteristics, outcomes and management
    Lo, Andre Chu Qiao
    McDonald, Sarah
    Wong, Kai Yuen
    [J]. BMJ CASE REPORTS, 2021, 14 (08)
  • [23] Management of pleomorphic dermal sarcoma
    Lonie, Sarah
    Yau, Benny
    Henderson, Michael
    Gyorki, David
    Angel, Christopher
    Webb, Angela
    [J]. ANZ JOURNAL OF SURGERY, 2020, 90 (11) : 2322 - 2324
  • [24] Morphological and immunohistochemical characteristics of atypical fibroxanthoma with a special emphasis on potential diagnostic pitfalls: a review
    Luzar, Bostjan
    Calonje, Eduardo
    [J]. JOURNAL OF CUTANEOUS PATHOLOGY, 2010, 37 (03) : 301 - 309
  • [25] Correction and clarification regarding AFX and pleomorphic dermal sarcoma
    McCalmont, Timothy H.
    [J]. JOURNAL OF CUTANEOUS PATHOLOGY, 2012, 39 (01) : 8 - 8
  • [26] Pleomorphic Dermal Sarcoma Adverse Histologic Features Predict Aggressive Behavior and Allow Distinction From Atypical Fibroxanthoma
    Miller, Keith
    Goodlad, John R.
    Brenn, Thomas
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2012, 36 (09) : 1317 - 1326
  • [27] Evaluation of the American Society of Anesthesiologists Physical Status Classification System in Risk Assessment for Plastic and Reconstructive Surgery Patients
    Miller, Travis J.
    Jeong, Haneol S.
    Davis, Kathryn
    Matthew, Anoop
    Lysikowski, Jerzy
    Cho, Min-Jeong
    Reed, Gary
    Kenkel, Jeffrey M.
    [J]. AESTHETIC SURGERY JOURNAL, 2014, 34 (03) : 448 - 456
  • [28] Mirza Basit, 2005, Australas J Dermatol, V46, P235, DOI 10.1111/j.1440-0960.2005.00190.x
  • [29] Extended surgical safety margins and ulceration are associated with an improved prognosis in pleomorphic dermal sarcomas
    Persa, O. D.
    Loquai, C.
    Wobser, M.
    Baltaci, M.
    Dengler, S.
    Kreuter, A.
    Volz, A.
    Laimer, M.
    Emberger, M.
    Doerler, M.
    Mauch, C.
    Helbig, D.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 (08) : 1577 - 1580
  • [30] Atypical Fibroxanthoma and Pleomorphic Dermal Sarcoma Updates on Classification and Management
    Soleymani, Teo
    Aasi, Sumaira Z.
    Novoa, Roberto
    Hollmig, S. Tyler
    [J]. DERMATOLOGIC CLINICS, 2019, 37 (03) : 253 - +